RSS Newsfeeds

See all RSS Newsfeeds

Jul 31, 2017 10:40 AM ET

Diagnostic and Therapeutic Developments across Global Healthcare

iCrowdNewswire - Jul 31, 2017

The “Diagnostic and Therapeutic Developments across Global Healthcare” report has been added to Research and Markets’ offering.

This Genetic Technology TOE depicts recent diagnostic and therapeutic advances across the global healthcare industry.

Clinical trial scenario for monoclonal antibody therapies for migraine are also depicted.

The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions.

The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Key Topics Covered:

1. Recent Diagnostic and Therapeutic Advances

– Advancing Epigenetic and Molecular Diagnostics across Urologic and Lung Cancers
– Expanded Collaboration for Novel Migraine Antibody Platform
– 3D Scaffold Platform for Organ Transplants
– Mobile App for Diabetes Management

2. Clinical Trial Analysis and Industry Interactions

– Clinical Trial Analysis
– Industry Interactions

For more information about this report visit https://www.researchandmarkets.com/research/q29flf/diagnostic_and

Contact Information:

Research and Markets,
Laura Wood,
Senior Manager.
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
Related Topics: Diagnostics (https://www.researchandmarkets.com/categories.asp?cat_id=59&campaign_id=q29flf)

Via iCrowdNewswire
View Related News >